Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Fri, October 9, 9:16 PM
| This Slide: #378 of 672 |
Slide #378. Cascadian Therapeutics, Inc. — Preferred Stock Offering
| Company: | Cascadian Therapeutics, Inc. (CASC) |
| Date announced: | 6/22/2016 |
| Shares Offered: | 35,000,000 |
| Date of Pricing: | 6/23/2016 |
| Price Per Share: | $0.80 |
| Preferred Stock Offering Details: | Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. As part of the offering, Cascadian Therapeutics also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. The offering is being conducted by means of a prospectus supplement. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or term of the offering. -updated 6/23- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced the pricing of the previously announced underwritten offering of 35,000,000 shares of its common stock at a price to the public of $0.80 per share, for expected gross proceeds of $28.0 million. As part of the common stock offering, Cascadian Therapeutics granted the underwriters a 30-day option to purchase 5,250,000 additional shares of Cascadian Therapeutics common stock. In addition, Cascadian Therapeutics agreed to sell 17,250 shares of its Series D Convertible Preferred Stock at a price of $800.00 per share directly to affiliates of BVF Partners L.P., which are existing stockholders and affiliates of a member of the board of directors of Cascadian Therapeutics, for expected gross proceeds of $13.8 million |
Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Co.'s primary development candidate, tucatinib, is an orally bioavailable, potent tyrosine kinase inhibitor that is selective for HER2, a growth factor receptor that is over-expressed in about 20.0% of breast cancers. Co. is developing tucatinib for the treatment of HER2-positive metastatic breast cancer. Co.'s earlier stage product candidate, CASC-578, is a checkpoint kinase 1 cell cycle inhibitor that is an orally available, small molecule kinase inhibitor and additionally Co. has an antibody against an immuno-oncology target known as TIGIT.
Open the CASC Page at Preferred Stock Channel »
|
|||||||||
|
|
Open the CASC Page at Preferred Stock Channel (in a new window) »
|
|
Free CASC Email Alerts:
Avg. Broker Rec.
  
|
Hold (2.40 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|
Browse preferred stock yield screens, safer-income pages, offerings research, valuation and liquidation-preference screens, and related market idea pages from across the channel network. These links are grouped by topic to make the list easier to scan. Preferred Yield and Income ScreensCore PreferredStockChannel pages focused on high-yield preferreds, socially responsible income ideas, and safer-income preferred research. Offerings, Structure, and Screening ToolsPages for recent preferred offerings, preferreds by index membership or industry, and insider-related screening ideas. Premium, Discount, and Relative Value ScreensPages centered on preferred stock pricing relative to liquidation preference and comparative value signals. Dividend and Cross-Network Income ResearchRelated dividend and income pages from across the network that support preferred-stock investors comparing income vehicles. Analyst and Broader Market ResearchBroader analyst and market pages that remain part of the live homepage inventory. |
|
|
